Department of Neurosurgery, Chinese Medicine Hospital of Guangdong Province, Guangzhou, China; The Second Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, China.
Guangzhou Huashang Vocational College, Guangzhou, China.
Prog Brain Res. 2020;258:369-379. doi: 10.1016/bs.pbr.2020.09.008. Epub 2020 Oct 24.
Glioma is the most common primary malignant brain tumor in adults and the patients have poor prognosis despite treatment with surgery, radiotherapy and chemotherapy. The anti-epileptic drug, valproic acid (VPA) as a HDAC inhibitors is often used in glioma patients even if the patients don't have brain tumors associated epilepsy (BAE). Some previous studies have found that VPA not only has anti-epileptic effect, but also has anti-glioma growth effect through enhance radiotherapy sensitivity or other mechanism. Then VPA is reported to improve the survival of glioma patients receiving chemoradiation therapy. In addition, there are limited researches have shown that VPA has a neuroprotective effect in protect normal cells and tissues from the deleterious effects of treatment of glioma, especially radiotherapy. We'll give a brief overview of these effects of VPA in glioma patients.
神经胶质瘤是成人中最常见的原发性恶性脑肿瘤,尽管采用手术、放疗和化疗治疗,患者预后仍较差。尽管没有脑肿瘤相关癫痫(BAE),抗癫痫药物丙戊酸(VPA)作为组蛋白去乙酰化酶抑制剂也常用于神经胶质瘤患者。一些先前的研究发现,VPA 不仅具有抗癫痫作用,而且通过增强放疗敏感性或其他机制还具有抗神经胶质瘤生长作用。随后,有报道称 VPA 可改善接受放化疗的神经胶质瘤患者的生存。此外,有限的研究表明,VPA 对保护正常细胞和组织免受神经胶质瘤治疗(尤其是放疗)的有害影响具有神经保护作用。我们将简要概述 VPA 在神经胶质瘤患者中的这些作用。